Moderna has opened the Moderna Innovation and Technology Centre (MITC), its new vaccine manufacturing and research and development (R&D) facility in Oxfordshire, UK.
The facility, located at the Harwell Science and Innovation Campus, is now authorised to produce messenger ribonucleic acid (mRNA) respiratory vaccines for the UK market.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is a result of Moderna’s decade-long partnership with the UK government, aimed at enhancing health resilience and stimulating economic growth.
MITC will manufacture mRNA vaccines for respiratory illnesses, supporting the National Health Service’s seasonal vaccination programmes.
The centre will conduct research into mRNA applications for rare diseases, cancer and immune disorders.
Moderna CEO Stéphane Bancel stated: “The opening of the Moderna Innovation and Technology Centre marks the first facility in the UK to manufacture an onshore supply of mRNA vaccines.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Our strategic partnership with the UK has already delivered more than 20 clinical trials across 110 sites nationwide, making Moderna the largest commercial sponsor of trials in the country.
“Together, we successfully delivered this vision from concept to operational readiness in under two years.”
The Oxfordshire facility has an annual production capacity of up to 100 million mRNA vaccine doses, with the potential to increase to 250 million doses during pandemics.
It also houses clinical R&D laboratories to analyse samples from global clinical trials.
The UK site is part of Moderna’s international network of advanced manufacturing centres, which includes locations in Canada and Australia.
In August 2025, Moderna received approval from Health Canada for its updated Covid-19 vaccine, Spikevax, which targets the SARS-CoV-2 LP.8.1 variant.
The updated vaccine, authorised for individuals aged six months and older, is planned for distribution in the 2025-2026 vaccination season.
mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
